scispace - formally typeset
R

Ray W. Fuller

Researcher at Eli Lilly and Company

Publications -  353
Citations -  11517

Ray W. Fuller is an academic researcher from Eli Lilly and Company. The author has contributed to research in topics: Serotonin & Dopamine. The author has an hindex of 56, co-authored 353 publications receiving 11355 citations. Previous affiliations of Ray W. Fuller include Indiana University.

Papers
More filters
Journal ArticleDOI

Vasopressin/Serotonin Interactions in the Anterior Hypothalamus Control Aggressive Behavior in Golden Hamsters

TL;DR: The present studies examine the neuroanatomical and neurochemical interaction between AVP and 5-HT at the level of the anterior hypothalamus (AH) in the control of offensive aggression in Syrian golden hamsters to suggest that5-HT inhibits fighting, in part, by antagonizing the aggression-promoting action of the AVP system.
Journal ArticleDOI

Uptake inhibitors increase extracellular serotonin concentration measured by brain microdialysis

TL;DR: The physiological role of the serotonin transporter on serotonin neuronal membranes apparently is to inactivate serotonin that has been released into the synaptic cleft, and serotonin neurons decrease their firing and release of serotonin to limit the magnitude of the increase in extracellular serotonin concentration.
Journal ArticleDOI

Effect of fluoxetine on serotonin and dopamine concentration in microdialysis fluid from rat striatum

TL;DR: The increased extracellular concentration of serotonin no doubt resulted from inhibition of the serotonin uptake carrier by fluoxetine, and the lack of change in dopamine is evidence for the specificity of action of this uptake inhibitor.
Journal ArticleDOI

Dopamine deficiency in the weaver mutant mouse

TL;DR: It is illustrated that weaver mice have specific deficiencies in the dopamine system and might provide a way of examining the biochemical and behavioral effects of long term dopamine deficiency and a way to examine drugs to treat dopamine-deficient states in vivo.
Journal ArticleDOI

Effect of an uptake inhibitor on serotonin metabolism in rat brain: Studies with 3-(p-trifluoromethylphenoxy)-n-methyl-3-phenylpropylamine (Lilly 110140)

TL;DR: Lilly 110140 had no effect on brain levels of tryptophan, serotonin, dopamine, or norepinephrine, but it decreased 5-hydroxyindoleacetic acid (5HIAA) levels, and reduced turnover was indicated by a decreased rate of fall in brain serotonin levels after p-chlorophenylalamine was given to inhibit serotonin synthesis.